Table 4.
Reported clinical series of IFX therapy in patients with BD-associated or idiopathic refractory PU
| Reference | PU type | Patient N° | IFX dose | Primary outcome measure | Responders (N/%) | Follow-up (months) |
|---|---|---|---|---|---|---|
| Sfikakis et al34 | BD | 5 | 5 mg/kg | Inflammation suppression | 5 (100%) | 1 |
| Joseph et al35 | BD, idiopathic | 5 | 5 mg/kg | Inflammation suppression | 4 (80%) | 6 |
| Sfikakis et al36 | BD | 15 | 5 mg/kg | Inflammation suppression | 19 (76%) | 8 |
| Ohno et al37 | BD | 13 | 5 mg/kg/10 mg/kg | Flare-up frequency | 10 (77%) | 3 |
| Wechsler et al38 | BD | 4 | 5 mg/kg | Inflammation suppression | 4 (100%) | 22 |
| Benitez-del Castillo et al39 | BD, idiopathic | 7 | 5 mg/kg | Inflammation suppression | 4 (57%) | 36 |
| Tugal-Tutkun et al40 | BD | 13 | 5 mg/kg | Inflammation suppression | 4/13 (31%) | 12 |
| Lindstedt et al41 | BD, idiopathic | 13 | 3 mg/kg | Inflammation suppression | 13/13 (100%) | 24 |
| Lanthier et al42 | BD | 4 | 5 mg/kg | Inflammation suppression | 2 (50%) | 11 |
| Suhler et al43 | BD, idiopathic | 23 | 5 mg/kg | See note* | 18 (78%) | 2 |
| Mushtaq B et al44 | BD | 3 | 5 mg/kg | Flare-up frequency | 3 (100%) | 16 |
| Abu El-Asrar AM45 | BD | 6 | 5 mg/kg | Inflammation suppression | 6 (100%) | 36 |
| Niccoli et al19 | BD | 12 | 5 mg/kg | Inflammation suppression | 7 (58%) | 24 |
| Accorinti et al46 | BD | 12 | 5 mg/kg | Flare-up frequency | 11 (92%) | 16 |
| Tognon et al47 | BD | 7 | 3 mg/kg 5 mg/kg |
Flare-up frequency | 6 (86%) | 23 |
| Al-Rayes et al48 | BD | 10 | 5 mg/kg | Flare-up frequency | 7 (70%) | 36 |
| Tabbara and Al-Hemidan49 | BD | 10 | 5 mg/kg | Flare-up frequency | NA | 30 |
| Yamada et al50 | BD | 17 | 5 mg/kg | Flare-up frequency | 6 | |
| Giardina et al51 | BD | 21 | 5 mg/kg | Inflammation suppression | 18 (86%) | 12 |
| Adán et al52 | BD | 4 | 5 mg/kg | Inflammation suppression | 2 (50%) | 12 |
| Yamada et al53 | BD | 23 | 5 mg/kg | Flare-up frequency | 10 (43%) | 20 |
| Sugita et al54 | BD | 20 | 5 mg/kg | Flare-up frequency | 15 (75%) | 28 |
*
Notes: Patients were considered responders if improved in at least one of four variables (visual acuity, control of intraocular inflammation, ability to taper concomitant medication therapy, improvement in inflammatory signs on FFA and/or OCT) and if they worsened in none.
Abbreviations: BD, Behçet’s disease; IFX, infliximab; NA, not applicable; PU, posterior uveitis; SD, standard deviation.